We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diatron MI and Medicon Hellas Sign Exclusive Supply Agreement

By LabMedica International staff writers
Posted on 14 Oct 2013
Diatron MI Plc (Budapest, Hungary) and Medicon Hellas SA (Gerakas, Greece) signed an exclusive supply agreement for an extensive range of high quality clinical chemistry reagents for use on the Diatron Pictus range of clinical chemistry analyzers in all international markets except the USA.

All reagents will be manufactured by Medicon Hellas, exclusively for Diatron and have been specifically designed with the Diatron analyzers in mind, so the combination of analyzer and reagents allows customers to employ features and benefits that are only normally possible on high cost clinical chemistry systems. More...
The reagent range will initially consist of 60 test parameters (substrates, enzymes, electrolytes, and specific proteins), which have been developed to meet the needs and demands of today’s modern clinical chemistry laboratory to have precision, linearity, sensitivity, on-board stability, and calibration stability.

Diatron will be exhibiting two new, bench top analyzers at Medica, Dusseldorf (November 20–23, 2013). The new version of the established Abacus 3CT hematology analyzer has been enhanced to make it even easier to use. In addition, Diatron will also be previewing a prototype version of the brand new Pictus 500 clinical chemistry analyzer.

“ We are excited by the new collaboration with Medicon as it will allow us to mutually grow our clinical chemistry business with our global distributor partners and to demonstrate to end-users our commitment to provide them with the full package—a cost effective system (analyzer & reagent) with complete support,“ said Ronald Backes, vice president of International Business- Diatron MI Plc.

“Medicon is delighted to enter into this agreement with Diatron, rewarding the time and effort we have put into developing specific reagents and tests for the Pictus analyzers. We are pleased that customers around the world will now be able to benefit from what Greek laboratories have experienced with the analyzer/reagent combination,” commented Sakis Mitropoulos, director, customer services, Medicon Hellas SA.

Related Links:

Diatron MI
Medicon Hellas



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.